Epigral Gestione

Gestione criteri di controllo 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Kaushal Soparkar

Amministratore delegato

₹43.9m

Compenso totale

Percentuale dello stipendio del CEO	9.2%
Mandato del CEO	8.5yrs
Proprietà del CEO	0.5%
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	8.5yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Kaushal Soparkar rispetto agli utili di Epigral?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	₹3b
Jun 30 2024	n/a	n/a	₹3b
Mar 31 2024	₹44m	₹4m	₹2b
Dec 31 2023	n/a	n/a	₹2b
Sep 30 2023	n/a	n/a	₹2b
Jun 30 2023	n/a	n/a	₹3b
Mar 31 2023	₹62m	₹4m	₹4b
Dec 31 2022	n/a	n/a	₹4b
Sep 30 2022	n/a	n/a	₹4b
Jun 30 2022	n/a	n/a	₹3b
Mar 31 2022	₹32m	₹4m	₹3b
Mar 31 2021	₹30m	₹3m	₹1b
Mar 31 2020	₹28m	₹4m	₹1b
Mar 31 2019	₹64m	₹4m	₹2b
Mar 31 2018	₹9m	₹4m	₹2b

Compensazione vs Mercato: La retribuzione totale di Kaushal ($USD 519.99K ) è superiore alla media delle aziende di dimensioni simili nel mercato Indian ($USD 355.29K ).

Compensazione vs guadagni: La retribuzione di Kaushal è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Kaushal Soparkar (41 yo)

8.5yrs

Mandato

₹43,907,000

Compensazione

Mr. Kaushal Ashisbhai Soparkar serves as Chief Executive Officer and until August 5, 2023 served as Managing Director and serves as Director of Epigral Limited (formerly known as Meghmani Finechem Limited)...

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Maulik Patel	Chairman & MD	8.5yrs	₹43.91m	7.53% ₹ 6.3b
Kaushal Soparkar	CEO & Executive Director	8.5yrs	₹43.91m	0.51% ₹ 431.5m
Kanubhai Patel	Independent Non-Executive Director	3.5yrs	₹700.00k	Nessun dato
Karana Patel	Non-Executive Director	8.5yrs	₹25.32m	1.68% ₹ 1.4b
Sanjay Asher	Independent Non-Executive Director	3.5yrs	₹500.00k	Nessun dato
Ankit Patel	Non-Executive Director	8.5yrs	₹41.27m	5.41% ₹ 4.5b
Manubhai Patel	Independent Non-Executive Director	7.5yrs	₹875.00k	Nessun dato
Darshan Patel	Non-Executive Director	8.5yrs	₹17.35m	2.29% ₹ 1.9b
Nirali Parikh	Independent Non-Executive (Woman) Director	9.7yrs	₹725.00k	Nessun dato
Raju Swamy	Independent Non-Executive Director	3.5yrs	₹400.00k	0.010% ₹ 8.4m

8.5yrs

Durata media

43yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 543332 sono considerati esperti (durata media dell'incarico 8.5 anni).

Epigral Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Epigral Limited, Annual General Meeting, Jul 09, 2024

Insufficient new directors

Insider recently bought ₹4.8m worth of stock

Meghmani Finechem Limited, Annual General Meeting, Jun 27, 2023

Insider recently bought ₹4.6m worth of stock

Meghmani Finechem Limited, Annual General Meeting, Jun 27, 2023

Recent updates

Second quarter 2025 earnings released: EPS: ₹19.57 (vs ₹9.14 in 2Q 2024)

Epigral Limited to Report Q2, 2025 Results on Nov 09, 2024

Investor sentiment improves as stock rises 16%

New minor risk - Share price stability

First quarter 2025 earnings released: EPS: ₹20.67 (vs ₹7.58 in 1Q 2024)

Epigral Limited to Report Q1, 2025 Results on Jul 24, 2024

Epigral Limited Approves Final Dividend for the Financial Year 2024

Investor sentiment improves as stock rises 16%

Upcoming dividend of ₹5.00 per share

Full year 2024 earnings released: EPS: ₹47.14 (vs ₹85.03 in FY 2023)

Dividend of ₹5.00 announced

Epigral Limited, Annual General Meeting, Jul 09, 2024

Insufficient new directors

Full year 2024 earnings released: EPS: ₹47.13 (vs ₹85.03 in FY 2023)

Epigral Limited Recommends Final Dividend for the Financial Year Ended March 31, 2024

Epigral Limited to Report Q4, 2024 Results on Apr 22, 2024

Investor sentiment improves as stock rises 22%

Investor sentiment improves as stock rises 22%

Third quarter 2024 earnings released: EPS: ₹11.81 (vs ₹18.58 in 3Q 2023)

Now 23% overvalued after recent price rise

Epigral Limited to Report Q3, 2024 Results on Jan 24, 2024

New minor risk - Profit margin trend

Second quarter 2024 earnings released: EPS: ₹9.14 (vs ₹22.04 in 2Q 2023)

Epigral Limited to Report Q2, 2024 Results on Nov 06, 2023

First quarter 2024 earnings released: EPS: ₹7.58 (vs ₹25.94 in 1Q 2023)

Meghmani Finechem Limited to Report Q1, 2024 Results on Aug 05, 2023

Meghmani Finechem Limited Approves Final Equity Dividend for the Financial Year 2022-2023

Upcoming dividend of ₹2.50 per share at 0.5% yield

Insider recently bought ₹4.8m worth of stock

Meghmani Finechem Limited Proposes Final Dividend to the Shareholders for Financial Year 2022- 2023

Full year 2023 earnings released: EPS: ₹85.03 (vs ₹60.84 in FY 2022)

Meghmani Finechem Limited, Annual General Meeting, Jun 27, 2023

Insider recently bought ₹4.6m worth of stock

Meghmani Finechem Limited, Annual General Meeting, Jun 27, 2023

Full year 2023 earnings released: EPS: ₹85.03 (vs ₹60.84 in FY 2022)

Investor sentiment improves as stock rises 18%

Chairman & MD recently bought ₹4.8m worth of stock

Chairman & MD recently bought ₹2.9m worth of stock

Insider recently bought ₹5.0m worth of stock

Third quarter 2023 earnings released: EPS: ₹18.68 (vs ₹23.85 in 3Q 2022)

Meghmani Finechem Limited Declares Maiden Interim Dividend for the Year Financial Year 2022-23, Payable on or After 08 February, 2023

Meghmani Finechem Limited to Report Q3, 2023 Results on Jan 19, 2023

Second quarter 2023 earnings released: EPS: ₹22.04 (vs ₹23.85 in 2Q 2022)

Investor sentiment deteriorated over the past week

First quarter 2023 earnings released: EPS: ₹25.94 (vs ₹7.89 in 1Q 2022)

Meghmani Finechem Limited to Report Q1, 2023 Results on Jul 21, 2022

Full year 2022 earnings released: EPS: ₹60.84 (vs ₹24.27 in FY 2021)

Meghmani Finechem Limited, Annual General Meeting, Jun 27, 2022

Investor sentiment improved over the past week

Full year 2022 earnings released: EPS: ₹60.84 (vs ₹24.27 in FY 2021)

Investor sentiment improved over the past week

Meghmani Finechem Limited to Report Fiscal Year 2022 Results on Apr 25, 2022

Investor sentiment improved over the past week

CEO, MD & Director recently bought ₹799k worth of stock

Insider recently bought ₹762k worth of stock

Investor sentiment improved over the past week

Insider recently bought ₹8.3m worth of stock

Investor sentiment improved over the past week

No independent directors

No independent directors

No independent directors

No independent directors

MD & Additional Director recently bought ₹5.0m worth of stock

No independent directors

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Membri del Consiglio di amministrazione